Search
Isavuconazole
go.drugbank.com/drugs/DB11633ApprovedInvestigationalIt is approved by the FDA and EMA for the treatment of invasive aspergillosis and mucormycosis. It works by inhibiting fungal cell membrane synthesis.
Etozoline
go.drugbank.com/drugs/DB08982ExperimentalEtozoline is marketed in Europe under the names Diulozin, Elkapin, and Etopinil. Etozoline is a loop diuretic.
Categories: High-Ceiling DiureticsLenalidomide
go.drugbank.com/drugs/DB00480ApprovedInvestigational[A228708] Available as oral capsules, lenalidomide is approved by the FDA and EU for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal
N-acetyltyrosine
go.drugbank.com/drugs/DB11102ApprovedInvestigationalN-acetyltyrosine, also referred to as N-acetyl-L-tyrosine, is used in place of as a tyrosine precursor. DB00135 is a non-essential amino acid with a polar side group. N-acetyltyrosine is administered as parenteral nutrition or intravenou...
Lorcaserin
go.drugbank.com/drugs/DB04871ApprovedInvestigationalWithdrawnIt has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety.
Tedisamil
go.drugbank.com/drugs/DB06200ExperimentalIt is currently being developed by Solvay and is currently under regulatory review by the United States Food and Drug Administration.
Antithrombin III human
go.drugbank.com/drugs/DB11598ApprovedInvestigationalA plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
Zanidatamab zovodotin
go.drugbank.com/drugs/DB15472ExperimentalAccording to Zymeworks, "ZW49 (zanidatamab zovodotin) is a bispecific anti-HER2 ADC that is based on the same antibody framework as [ZW25] but armed with a cytotoxic payload." … [L8234] It is being investigated for several indications characterized by HER2 expression including breast and gastric cancers that have progressed or are refractory to existing HER2-targeted therapies
DaxibotulinumtoxinA
go.drugbank.com/drugs/DB17929ApprovedInvestigational[A261075, L47860] DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines.